Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis.

Obici L, Suhr OB.

Clin Auton Res. 2019 Aug 26. doi: 10.1007/s10286-019-00628-6. [Epub ahead of print] Review.

PMID:
31452022
2.

Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.

Dyck PJB, González-Duarte A, Obici L, Polydefkis M, Wiesman JF, Antonino I, Litchy WJ, Dyck PJ.

J Neurol Sci. 2019 Aug 8;405:116424. doi: 10.1016/j.jns.2019.116424. [Epub ahead of print] Review.

3.

Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers.

Papa R, Rusmini M, Volpi S, Caorsi R, Picco P, Grossi A, Caroli F, Bovis F, Musso V, Obici L, Castana C, Ravelli A, Van Gijn ME, Ceccherini I, Gattorno M.

Rheumatology (Oxford). 2019 Aug 13. pii: kez376. doi: 10.1093/rheumatology/kez376. [Epub ahead of print] No abstract available.

PMID:
31410474
4.

Assessment of patients with hereditary transthyretin amyloidosis - understanding the impact of management and disease progression.

Conceição I, Coelho T, Rapezzi C, Parman Y, Obici L, Galán L, Rousseau A.

Amyloid. 2019 Sep;26(3):103-111. doi: 10.1080/13506129.2019.1627312. Epub 2019 Jul 24.

PMID:
31339362
5.

Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers

Papa R, Rusmini M, Volpi S, Caorsi R, Picco P, Grossi A, Caroli F, Bovis F, Musso V, Obici L, Castana C, Ravelli A, Van Gijn ME, Ceccherini I, Gattorno M.

Rheumatology (Oxford). 2019 Jul 19. pii: kez270. doi: 10.1093/rheumatology/kez270. [Epub ahead of print]

PMID:
31325311
6.

Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.

Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, Gospodinova M, Obici L, Rapezzi C, Garcia-Pavia P.

JACC Heart Fail. 2019 Aug;7(8):709-716. doi: 10.1016/j.jchf.2019.04.010. Epub 2019 Jul 10. Review.

7.

Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.

Gertz MA, Scheinberg M, Waddington-Cruz M, Heitner SB, Karam C, Drachman B, Khella S, Whelan C, Obici L.

Expert Rev Clin Pharmacol. 2019 Aug;12(8):701-711. doi: 10.1080/17512433.2019.1635008. Epub 2019 Jul 3. Review.

PMID:
31268366
8.

A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors.

Bertoni A, Carta S, Baldovini C, Penco F, Balza E, Borghini S, Di Duca M, Ognio E, Signori A, Nozza P, Schena F, Castellani P, Pastorino C, Perrone C, Obici L, Martini A, Ceccherini I, Gattorno M, Rubartelli A, Chiesa S.

J Allergy Clin Immunol. 2019 Jun 10. pii: S0091-6749(19)30757-2. doi: 10.1016/j.jaci.2019.05.034. [Epub ahead of print]

PMID:
31194989
9.

Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (TRAPS).

Lucherini OM, Vitale A, Obici L, Sota J, Frediani B, Merlini G, Rigante D, Cantarini L.

Clin Exp Rheumatol. 2019 May 30. [Epub ahead of print] No abstract available.

PMID:
31172924
10.

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients.

Tasaki M, Milani P, Foli A, Verga L, Obici L, Basset M, Bozzola M, Ferraro G, Nuvolone M, Morbini P, Capello G, Ueda M, Obayashi K, Paulli M, Ando Y, Merlini G, Palladini G, Lavatelli F.

Blood. 2019 Jul 18;134(3):320-323. doi: 10.1182/blood.2019000420. Epub 2019 Jun 6. No abstract available.

PMID:
31171502
11.

Burden of hereditary transthyretin amyloidosis on quality of life.

Yarlas A, Gertz MA, Dasgupta NR, Obici L, Pollock M, Ackermann EJ, Lovley A, Kessler AS, Patel PA, White MK, Guthrie SD.

Muscle Nerve. 2019 Aug;60(2):169-175. doi: 10.1002/mus.26515. Epub 2019 Jun 13.

PMID:
31093980
12.

Classification criteria for autoinflammatory recurrent fevers.

Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, Anton J, Arostegui JI, Barron K, Ben-Cherit E, Brogan PA, Cantarini L, Ceccherini I, De Benedetti F, Dedeoglu F, Demirkaya E, Frenkel J, Goldbach-Mansky R, Gul A, Hentgen V, Hoffman H, Kallinich T, Kone-Paut I, Kuemmerle-Deschner J, Lachmann HJ, Laxer RM, Livneh A, Obici L, Ozen S, Rowczenio D, Russo R, Shinar Y, Simon A, Toplak N, Touitou I, Uziel Y, van Gijn M, Foell D, Garassino C, Kastner D, Martini A, Sormani MP, Ruperto N; Eurofever Registry and the Paediatric Rheumatology International Trials Organisation (PRINTO).

Ann Rheum Dis. 2019 Aug;78(8):1025-1032. doi: 10.1136/annrheumdis-2019-215048. Epub 2019 Apr 24. Review.

PMID:
31018962
13.

Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis.

Buxbaum JN, Brannagan T 3rd, Buades-Reinés J, Cisneros E, Conceicao I, Kyriakides T, Merlini G, Obici L, Plante-Bordeneuve V, Rousseau A, Sekijima Y, Imai A, Waddington Cruz M, Yamada M.

Amyloid. 2019 Mar;26(1):10-14. doi: 10.1080/13506129.2018.1554563. Epub 2019 Jan 24.

PMID:
30675806
14.

Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.

Kristen AV, Ajroud-Driss S, Conceição I, Gorevic P, Kyriakides T, Obici L.

Neurodegener Dis Manag. 2019 Feb;9(1):5-23. doi: 10.2217/nmt-2018-0033. Epub 2018 Nov 27.

15.

Seek and You Shall Find: Is Subclinical Amyloid More Common Than Expected?

Obici L, Merlini G.

Mayo Clin Proc. 2018 Nov;93(11):1546-1548. doi: 10.1016/j.mayocp.2018.09.008. No abstract available.

PMID:
30392540
16.

An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome.

Federici S, Vanoni F, Ben-Chetrit E, Cantarini L, Frenkel J, Goldbach-Mansky R, Gul A, Hoffman H, Koné-Paut I, Kuemmerle-Deschner J, Lachmann HJ, Martini A, Obici L, Ozen S, Simon A, Hofer M, Ruperto N, Gattorno M; Eurofever and the Pediatric Rheumatology International Trials Organization (PRINTO).

J Rheumatol. 2019 Apr;46(4):429-436. doi: 10.3899/jrheum.180056. Epub 2018 Nov 1.

PMID:
30385706
17.

Becoming familiar with hereditary transthyretin amyloidosis, a treatable neuropathy.

Obici L.

Arq Neuropsiquiatr. 2018 Sep;76(9):573-574. doi: 10.1590/0004-282X20180102. No abstract available.

18.

Progressive axonal polyneuropathy in a mitochondrial disorder: an uncommon association with familial amyloid neuropathy.

Luigetti M, Primiano G, Bisogni G, Cuccagna C, Carrozzo R, Obici L, Bernardo D, Sancricca C, Servidei S.

Amyloid. 2018 Dec;25(4):261-262. doi: 10.1080/13506129.2018.1506919. Epub 2018 Sep 7. No abstract available.

PMID:
30193540
19.

Plasminogen activation triggers transthyretin amyloidogenesis in vitro.

Mangione PP, Verona G, Corazza A, Marcoux J, Canetti D, Giorgetti S, Raimondi S, Stoppini M, Esposito M, Relini A, Canale C, Valli M, Marchese L, Faravelli G, Obici L, Hawkins PN, Taylor GW, Gillmore JD, Pepys MB, Bellotti V.

J Biol Chem. 2018 Sep 14;293(37):14192-14199. doi: 10.1074/jbc.RA118.003990. Epub 2018 Jul 17.

20.

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T.

N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.

21.

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.

De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Koné-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G.

N Engl J Med. 2018 May 17;378(20):1908-1919. doi: 10.1056/NEJMoa1706314.

22.

Renal involvement in autoinflammatory diseases and inflammasome-mediated chronic kidney damage.

Scarpioni R, Obici L.

Clin Exp Rheumatol. 2018 Jan-Feb;36 Suppl 110(1):54-60. Epub 2018 May 3. Review.

23.

Autoinflammatory diseases as a cause of acute abdominal pain in the emergency department.

Maconi G, Obici L, Carmagnola S, Guzzetti S.

Clin Exp Rheumatol. 2018 Jan-Feb;36 Suppl 110(1):39-43. Epub 2018 May 3. Review.

24.

Updated overview of molecular pathways involved in the most common monogenic autoinflammatory diseases.

Lucherini OM, Rigante D, Sota J, Fabiani C, Obici L, Cattalini M, Gattorno M, Cantarini L.

Clin Exp Rheumatol. 2018 Jan-Feb;36 Suppl 110(1):3-9. Epub 2018 May 3. Review.

25.

Cryopyrin-associated Periodic Syndromes in Italian Patients: Evaluation of the Rate of Somatic NLRP3 Mosaicism and Phenotypic Characterization.

Lasigliè D, Mensa-Vilaro A, Ferrera D, Caorsi R, Penco F, Santamaria G, Di Duca M, Amico G, Nakagawa K, Antonini F, Tommasini A, Consolini R, Insalaco A, Cattalini M, Obici L, Gallizzi R, Santarelli F, Del Zotto G, Severino M, Rubartelli A, Ravazzolo R, Martini A, Ceccherini I, Nishikomori R, Gattorno M, Arostegui JI, Borghini S.

J Rheumatol. 2017 Nov;44(11):1667-1673. doi: 10.3899/jrheum.170041. Epub 2017 Sep 15.

PMID:
28916543
26.

Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system.

Gonçalves NP, Moreira J, Martins D, Vieira P, Obici L, Merlini G, Saraiva M, Saraiva MJ.

J Neuroinflammation. 2017 Jun 6;14(1):115. doi: 10.1186/s12974-017-0891-9.

27.

Prognostication of survival and progression to dialysis in AA amyloidosis.

Palladini G, Riva E, Basset M, Russo F, Milani P, Pasquinucci E, Foli A, Lavatelli F, Nuvolone M, Casarini S, Obici L, Merlini G.

Amyloid. 2017 Mar;24(sup1):136-137. doi: 10.1080/13506129.2017.1289917. No abstract available.

PMID:
28434292
28.

Circulating intercellular adhesion molecule 1 (sICAM-1) in tumour necrosis factor receptor-associated periodic syndrome (TRAPS).

Cantarini L, Pucino V, Vitale A, Lucherini OM, Obici L, Matarese G.

Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 104(2):13-14. Epub 2017 Apr 4. No abstract available.

29.

Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy.

Cortese A, Vegezzi E, Lozza A, Alfonsi E, Montini A, Moglia A, Merlini G, Obici L.

J Neurol Neurosurg Psychiatry. 2017 May;88(5):457-458. doi: 10.1136/jnnp-2016-315262. Epub 2017 Feb 10. No abstract available.

30.

Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney.

Obici L, Nuvolone M, Merlini G.

Kidney Int. 2016 Sep;90(3):479-81. doi: 10.1016/j.kint.2016.05.029.

PMID:
27521110
31.

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.

Torene R, Nirmala N, Obici L, Cattalini M, Tormey V, Caorsi R, Starck-Schwertz S, Letzkus M, Hartmann N, Abrams K, Lachmann H, Gattorno M.

Ann Rheum Dis. 2017 Jan;76(1):303-309. doi: 10.1136/annrheumdis-2016-209335. Epub 2016 Jul 29.

32.

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.

Schmidt HH, Barroso F, González-Duarte A, Conceição I, Obici L, Keohane D, Amass L.

Muscle Nerve. 2016 Sep;54(3):353-60. doi: 10.1002/mus.25210.

33.

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.

Gattorno M, Obici L, Cattalini M, Tormey V, Abrams K, Davis N, Speziale A, Bhansali SG, Martini A, Lachmann HJ.

Ann Rheum Dis. 2017 Jan;76(1):173-178. doi: 10.1136/annrheumdis-2015-209031. Epub 2016 Jun 7.

34.

Clinical Pregenetic Screening for Stroke Monogenic Diseases: Results From Lombardia GENS Registry.

Bersano A, Markus HS, Quaglini S, Arbustini E, Lanfranconi S, Micieli G, Boncoraglio GB, Taroni F, Gellera C, Baratta S, Penco S, Mosca L, Grasso M, Carrera P, Ferrari M, Cereda C, Grieco G, Corti S, Ronchi D, Bassi MT, Obici L, Parati EA, Pezzini A, De Lodovici ML, Verrengia EP, Bono G, Mazucchelli F, Zarcone D, Calloni MV, Perrone P, Bordo BM, Colombo A, Padovani A, Cavallini A, Beretta S, Ferrarese C, Motto C, Agostoni E, Molini G, Sasanelli F, Corato M, Marcheselli S, Sessa M, Comi G, Checcarelli N, Guidotti M, Uccellini D, Capitani E, Tancredi L, Arnaboldi M, Incorvaia B, Tadeo CS, Fusi L, Grampa G, Merlini G, Trobia N, Comi GP, Braga M, Vitali P, Baron P, Grond-Ginsbach C, Candelise L; Lombardia GENS Group*.

Stroke. 2016 Jul;47(7):1702-9. doi: 10.1161/STROKEAHA.115.012281. Epub 2016 May 31.

PMID:
27245348
35.

Erratum to: Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.

Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D.

J Neurol. 2016 May;263(5):925-926. doi: 10.1007/s00415-016-8116-1. No abstract available.

PMID:
27098978
36.

Clinical Characteristics of Patients Carrying the Q703K Variant of the NLRP3 Gene: A 10-year Multicentric National Study.

Naselli A, Penco F, Cantarini L, Insalaco A, Alessio M, Tommasini A, Maggio C, Obici L, Gallizi R, Cimmino M, Signa S, Lucherini OM, Carta S, Caroli F, Martini A, Rubartelli A, Ceccherini I, Gattorno M.

J Rheumatol. 2016 Jun;43(6):1093-100. doi: 10.3899/jrheum.150962. Epub 2016 Apr 1.

PMID:
27036377
37.

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.

Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D.

J Neurol. 2016 May;263(5):916-924. doi: 10.1007/s00415-016-8064-9. Epub 2016 Mar 16. Erratum in: J Neurol. 2016 May;263(5):925-926.

PMID:
26984605
38.

Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis.

Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, Kyriakides T; European Network for TTR-FAP (ATTReuNET).

Curr Opin Neurol. 2016 Feb;29 Suppl 1:S27-35. doi: 10.1097/WCO.0000000000000290. Review.

39.

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy.

Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, Slama MS, Hazenberg BP, Coelho T; European Network for TTR-FAP (ATTReuNET).

Curr Opin Neurol. 2016 Feb;29 Suppl 1:S14-26. doi: 10.1097/WCO.0000000000000289. Review.

40.

Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP.

Parman Y, Adams D, Obici L, Galán L, Guergueltcheva V, Suhr OB, Coelho T; European Network for TTR-FAP (ATTReuNET).

Curr Opin Neurol. 2016 Feb;29 Suppl 1:S3-S13. doi: 10.1097/WCO.0000000000000288. Review.

41.

"Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.

Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L.

J Peripher Nerv Syst. 2016 Mar;21(1):5-9. doi: 10.1111/jns.12153. Review.

42.

Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome.

Pucino V, Lucherini OM, Perna F, Obici L, Merlini G, Cattalini M, La Torre F, Maggio MC, Lepore MT, Magnotti F, Galgani M, Galeazzi M, Marone G, De Rosa V, Talarico R, Cantarini L, Matarese G.

J Leukoc Biol. 2016 May;99(5):761-9. doi: 10.1189/jlb.3A0915-399R. Epub 2015 Nov 23.

PMID:
26598380
43.

Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases.

Rusmini M, Federici S, Caroli F, Grossi A, Baldi M, Obici L, Insalaco A, Tommasini A, Caorsi R, Gallo E, Olivieri AN, Marzano A, Coviello D, Ravazzolo R, Martini A, Gattorno M, Ceccherini I.

Ann Rheum Dis. 2016 Aug;75(8):1550-7. doi: 10.1136/annrheumdis-2015-207701. Epub 2015 Sep 17.

PMID:
26386126
44.

Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study.

Adams D, Coelho T, Obici L, Merlini G, Mincheva Z, Suanprasert N, Bettencourt BR, Gollob JA, Gandhi PJ, Litchy WJ, Dyck PJ.

Neurology. 2015 Aug 25;85(8):675-82. doi: 10.1212/WNL.0000000000001870. Epub 2015 Jul 24.

45.

Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case-control study.

Muiesan ML, Salvetti M, Paini A, Agabiti Rosei C, Rubagotti G, Negrinelli A, Gregorini G, Cancarini G, Calabresi L, Franceschini G, Obici L, Perlini S, Merlini G, Agabiti Rosei E.

Amyloid. 2015;22(3):187-93. doi: 10.3109/13506129.2015.1066771. Epub 2015 Jul 25.

PMID:
26193960
46.

The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway.

Greco E, Aita A, Galozzi P, Gava A, Sfriso P, Negm OH, Tighe P, Caso F, Navaglia F, Dazzo E, De Bortoli M, Rampazzo A, Obici L, Donadei S, Merlini G, Plebani M, Todd I, Basso D, Punzi L.

Arthritis Res Ther. 2015 Apr 3;17:93. doi: 10.1186/s13075-015-0604-7.

47.

Etiology of amyloidosis determines myocardial 99mTc-DPD uptake in amyloidotic cardiomyopathy.

Longhi S, Bonfiglioli R, Obici L, Gagliardi C, Milandri A, Lorenzini M, Guidalotti PL, Merlini G, Rapezzi C.

Clin Nucl Med. 2015 May;40(5):446-7. doi: 10.1097/RLU.0000000000000741.

PMID:
25742226
48.

A practical approach to the diagnosis of systemic amyloidoses.

Fernández de Larrea C, Verga L, Morbini P, Klersy C, Lavatelli F, Foli A, Obici L, Milani P, Capello GL, Paulli M, Palladini G, Merlini G.

Blood. 2015 Apr 2;125(14):2239-44. doi: 10.1182/blood-2014-11-609883. Epub 2015 Jan 30.

49.

Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis.

Gregorini G, Izzi C, Ravani P, Obici L, Dallera N, Del Barba A, Negrinelli A, Tardanico R, Nardi M, Biasi L, Scalvini T, Merlini G, Scolari F.

Kidney Int. 2015 Jun;87(6):1223-9. doi: 10.1038/ki.2014.389. Epub 2015 Jan 7.

50.

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Palladini G, Milani P, Foli A, Vidus Rosin M, Basset M, Lavatelli F, Nuvolone M, Obici L, Perlini S, Merlini G.

Leukemia. 2014 Dec;28(12):2311-6. doi: 10.1038/leu.2014.227. Epub 2014 Jul 25.

PMID:
25059496

Supplemental Content

Support Center